Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
<p><strong>Background:</strong> Glioblastoma is the most common and aggressive primary brain tumor with extremely poor prognosis, highlighting an urgent need for developing novel treatment options. Identifying epigenetic vulnerabilities of cancer cells can provide excellen...
Автори: | Ozyerli-Goknar, E, Kala, EY, Aksu, AC, Bulut, I, Cingöz, A, Nizamuddin, S, Biniossek, M, Seker-Polat, F, Morova, T, Aztekin, C, Kung, SHY, Syed, H, Tuncbag, N, Gönen, M, Philpott, M, Cribbs, AP, Acilan, C, Lack, NA, Onder, TT, Timmers, HTM, Bagci-Onder, T |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
BioMed Central
2023
|
Схожі ресурси
Схожі ресурси
-
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
за авторством: Ezgi Ozyerli-Goknar, та інші
Опубліковано: (2023-11-01) -
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
за авторством: Yedier-Bayram, O, та інші
Опубліковано: (2022) -
The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma
за авторством: Ozyerli-Goknar, E, та інші
Опубліковано: (2019) -
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
за авторством: Saraç, H, та інші
Опубліковано: (2019) -
Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma
за авторством: Filiz Senbabaoglu, та інші
Опубліковано: (2020-12-01)